Use and effectiveness of a fixed‐ratio combination of insulin degludec/liraglutide (IDegLira) in a real‐world population with type 2 diabetes: results from a European …
H Price, M Blüher, R Prager, TM Phan… - Diabetes, Obesity …, 2018 - Wiley Online Library
Aims To describe the real‐world use and effectiveness of IDegLira, a fixed‐ratio combination
of the basal insulin degludec, and the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) …
of the basal insulin degludec, and the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) …
Initiating titratable fixed-ratio combinations of basal insulin analogs and glucagon-like peptide-1 receptor agonists: what you need to know
N Skolnik, D Hinnen, Y Kiriakov, ML Magwire… - Clinical …, 2018 - Am Diabetes Assoc
IN BRIEF Titratable fixed-ratio combinations (FRCs) of a basal insulin and a glucagon-like
peptide-1 (GLP-1) receptor agonist are new therapeutic options for people with type 2 …
peptide-1 (GLP-1) receptor agonist are new therapeutic options for people with type 2 …
Insulin/glucagon-like peptide-1 receptor agonist combination therapy for the treatment of type 2 diabetes: are two agents better than one?
VR Aroda, JR Arulandu, AJ Cannon - Clinical Diabetes, 2018 - Am Diabetes Assoc
IN BRIEF Given the progressive nature of type 2 diabetes, treatment intensification is usually
necessary to maintain glycemic control. However, for a variety of reasons, treatment is often …
necessary to maintain glycemic control. However, for a variety of reasons, treatment is often …
[HTML][HTML] Eficacia y seguridad de IdegLira para la intensificación del tratamiento en la diabetes tipo 2
JE Costa Gil, MC Faingold, LE Litwak… - Medicina (Buenos …, 2018 - SciELO Argentina
La diabetes mellitus es una verdadera pandemia; la diabetes tipo 2 en particular, con su
carácter progresivo, constituye un grave problema de salud. A pesar de los avances e …
carácter progresivo, constituye un grave problema de salud. A pesar de los avances e …